← Back to Screener
Atrium Therapeutics, Inc. Common Stock (RNA)
Price$14.30
Favorite Metrics
Price vs S&P 500 (26W)-79.79%
Price vs S&P 500 (4W)0.26%
Market Capitalization$239.40M
All Metrics
Book Value / Share (Quarterly)$6.98
P/TBV (Annual)0.80x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)58.44%
Cash Flow / Share (Quarterly)$-4.06
Price vs S&P 500 (YTD)-84.16%
Net Profit Margin (TTM)-1995.34%
EPS (TTM)$-4.17
10-Day Avg Trading Volume0.55M
EPS Excl Extra (TTM)$-2.99
Revenue Growth (5Y)36.26%
EPS (Annual)$-2.89
ROI (Annual)-35.34%
Net Profit Margin (5Y Avg)-1796.59%
Cash / Share (Quarterly)$7.32
Revenue Growth QoQ (YoY)-71.11%
ROA (Last FY)-592.61%
Revenue Growth TTM (YoY)22.02%
EBITD / Share (TTM)$-3.22
ROE (5Y Avg)-28.11%
Operating Margin (TTM)-2191.00%
Cash Flow / Share (Annual)$-2.49
P/B Ratio1.20x
P/B Ratio (Quarterly)0.90x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)91.25x
Net Interest Coverage (TTM)-2.35x
ROA (TTM)-33.70%
EPS Growth QoQ (YoY)13.99%
EPS Incl Extra (Annual)$-2.89
Current Ratio (Annual)0.07x
Quick Ratio (Quarterly)0.03x
3-Month Avg Trading Volume2.09M
52-Week Price Return-44.06%
Revenue / Employee (TTM)$54,495
Tangible BV / Share (Quarterly)$6.98
P/S Ratio (Annual)12.86x
Asset Turnover (Annual)2.23x
52-Week High$73.06
Operating Margin (5Y Avg)-1959.94%
EPS Excl Extra (Annual)$-2.89
CapEx CAGR (5Y)96.69%
26-Week Price Return-71.05%
Quick Ratio (Annual)0.03x
13-Week Price Return-80.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.07x
Enterprise Value$239.4
Revenue / Share Growth (5Y)13.23%
Asset Turnover (TTM)0.02x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-266.64%
Cash / Share (Annual)$8.75
3-Month Return Std Dev162.52%
Net Income / Employee (TTM)$-1,087,355
ROE (Last FY)-36.27%
EPS Basic Excl Extra (Annual)$-2.89
Receivables Turnover (TTM)19.72x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.99
ROI (TTM)-44.34%
P/S Ratio (TTM)45.76x
Pretax Margin (5Y Avg)-1796.59%
Revenue / Share (Annual)$1.09
Tangible BV / Share (Annual)$8.29
Price vs S&P 500 (52W)-79.16%
EPS Growth TTM (YoY)8.34%
Year-to-Date Return-80.02%
5-Day Price Return8.35%
EPS Normalized (Annual)$-2.89
ROA (5Y Avg)-24.50%
Net Profit Margin (Annual)-265.88%
Month-to-Date Return7.78%
Cash Flow / Share (TTM)$-2.93
EBITD / Share (Annual)$-2.88
Operating Margin (Annual)-266.58%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-28.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.99
P/TBV (Quarterly)0.90x
P/B Ratio (Annual)0.76x
Pretax Margin (TTM)-1995.34%
Book Value / Share (Annual)$8.29
Price vs S&P 500 (13W)-83.00%
Beta1.10x
P/FCF (Annual)4.27x
Revenue / Share (TTM)$0.15
ROE (TTM)-40.30%
52-Week Low$11.95
Analyst Recommendations
Apr 2026
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RNAAtrium Therapeutics, Inc. Common Stock | 45.76x | 22.02% | — | — | $14.30 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Atrium Therapeutics develops RNA-based therapeutics for genetic forms of cardiomyopathy. The company's proprietary platform uses ligand-based targeting to deliver RNA therapies directly to heart tissue. Current pipeline programs focus on cardiomyopathies associated with PRKAG2 and PLN gene mutations.